Patents by Inventor Ronald W. Lauener

Ronald W. Lauener has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzylated PDE4 inhibitors
    Patent number: 7459479
    Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.
    Type: Grant
    Filed: March 8, 2007
    Date of Patent: December 2, 2008
    Assignee: Biolipox AB
    Inventors: Ronald W. Lauener, David L. Burgoyne, Patrick J. Rebstein, Lloyd F. Mackenzie, Yuanlin Zhou, Yaping Shen
  • BENZYLATED PDE4 INHIBITORS
    Publication number: 20080287522
    Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.
    Type: Application
    Filed: July 21, 2008
    Publication date: November 20, 2008
    Applicant: BIOLIPOX AB
    Inventors: Ronald W. Lauener, David L. Burgoyne, Patrick J. Rebstein, Lloyd F. Mackenzie, Yuanlin Zhou, Yaping Shen
  • Benzylated PDE4 inhibitors
    Patent number: 7446129
    Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: November 4, 2008
    Assignee: Biolipox AB
    Inventors: Ronald W Lauener, David L Burgoyne, Patrick J Rebstein, Lloyd F Mackenzie, Yuanlin Zhou, Yaping Shen
  • Substituted &ggr;-phenyl-&Dgr;-lactams and uses related thereto
    Patent number: 6770658
    Abstract: &ggr;-Phenyl-substituted &Dgr;-lactams are disclosed. They may be formulated into pharmaceutical compositions, and/or used in the treatment or prevention of inflammation or other conditions or disease states.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: August 3, 2004
    Assignee: Inflazyme Pharmaceuticals Ltd.
    Inventors: Yaping Shen, David L. Burgoyne, Ronald W. Lauener, Yuanlin Zhou, Patrick J. Rebstein, Samuel D. M. Abraham
  • Benzylated PDE4 inhibitors
    Publication number: 20030220352
    Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.
    Type: Application
    Filed: March 18, 2003
    Publication date: November 27, 2003
    Applicant: Inflazyme Pharmaceuticals Ltd.
    Inventors: Ronald W. Lauener, David L. Burgoyne, Patrick J. Rebstein, Lloyd F. MacKenzie, Yuanlin Zhou, Yaping Shen
  • Substituted gamma-phenyl-delta-lactams and uses related thereto
    Publication number: 20030186943
    Abstract: &ggr;-Phenyl-substituted &Dgr;-lactams are disclosed. They may be formulated into pharmaceutical compositions, and/or used in the treatment or prevention of inflammation or other conditions or disease states.
    Type: Application
    Filed: October 1, 2002
    Publication date: October 2, 2003
    Applicant: Inflazyme Pharmaceuticals Ltd.
    Inventors: Yaping Shen, David L. Burgoyne, Ronald W. Lauener, Yuanlin Zhou, Patrick J. Rebstein, Samuel D. M. Abraham
  • Benzylated PDE4 inhibitors
    Patent number: 6555572
    Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: April 29, 2003
    Assignee: Inflazyme Pharmaceuticals Ltd.
    Inventors: Ronald W. Lauener, David L. Burgoyne, Patrick J. Rebstein, Lloyd F. Mackenzie, Yuanlin Zhou, Yaping Shen
  • Substituted &ggr;-phenyl-&Dgr;-lactones and analogs thereof and uses related thereto
    Patent number: 6458829
    Abstract: &ggr;-Phenyl-substituted &Dgr;-lactones and analogs thereof, including lactams, are disclosed. They may be formulated into pharmaceutical compositions, and/or used in the treatment or prevention of inflammation or other conditions or disease states.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: October 1, 2002
    Assignee: Inflazyme Pharmaceuticals Ltd.
    Inventors: Yaping Shen, David L. Burgoyne, Ronald W. Lauener, Yuanlin Zhou, Patrick J. Rebstein, Samuel D. M. Abraham
  • Benzylated PDE4 inhibitors
    Publication number: 20020028842
    Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.
    Type: Application
    Filed: March 16, 2001
    Publication date: March 7, 2002
    Inventors: Ronald W. Lauener, David L. Burgoyne, Patrick J. Rebstein, Lloyd F. Mackenzie, Yuanlin Zhou, Yaping Shen